Parathyroid hormone (1-34) (human) in VC Models

Parathyroid hormone (1-34) (human) is a practical research tool for experiments that need a defined, biologically active PTH stimulus rather than an undefined endocrine mixture. The fragment contains the first 34 amino acids of human parathyroid hormone and retains receptor-active signaling through PTH1R and PTH2R. That makes it useful across bone metabolism research, serum calcium regulation, receptor pharmacology, and chronic kidney disease-associated valvular calcification studies.

The most productive way to use this reagent is to treat it as a controlled perturbation. A receptor-proximal cAMP assay can establish activity, while endothelial, valvular interstitial cell, organoid, or animal experiments can determine how PTH signaling changes tissue phenotype. APExBIO supplies the research-use product as SKU A1129; it is not intended for diagnostic or medical use.

Setup and principle overview

What the PTH (1-34) peptide fragment contributes

The Parathyroid hormone (1-34) (human) product is a defined polypeptide with a molecular weight of 4117.72 Da. Its documented receptor-binding IC₅₀ is 2 nM, while its reported IC₅₀ for cAMP production in receptor-expressing human kidney 293 cells is 0.22 nM; inositol phosphate synthesis is stimulated at concentrations of at least 24 nM, according to the product information. These values are best used to design a broad pilot range, not to assume that every cell type has the same sensitivity.

Because 1 nM of a 4117.72-Da peptide is approximately 4.12 ng/mL, researchers can report both molar and mass concentrations without ambiguity. PTH1R-linked cAMP is a useful early confirmation of receptor engagement. Higher concentrations may be relevant when the experimental question concerns inositol phosphate signaling, transcriptional remodeling, or longer-term phenotypic changes. A pulse exposure and a sustained exposure should be considered separate biological conditions: they may produce different downstream outcomes even when the nominal concentration is identical.

Match the assay to the biological question

For PTH/PTHrP receptor signaling, begin with cAMP or receptor-binding assays. For serum calcium regulation or bone biology, combine PTH exposure with calcium, phosphate, alkaline phosphatase, mineral deposition, or bone-mass endpoints. For CKD-related valvular calcification, do not rely on calcium staining alone. Measure endothelial integrity, EndMT, paracrine signaling, and osteogenic activation of valvular interstitial cells so that the experiment distinguishes an initiating endothelial event from a late mineralization phenotype.

Step-by-step workflow and protocol enhancements

1. Define the model and controls. Include untreated vehicle controls, a PTH concentration series, and—where possible—a receptor-pathway control or genetic comparator. In endothelial experiments, maintain a non-endothelial control population to identify changes that are specific to valve endothelium rather than general peptide stress.
2. Prepare the reagent consistently. The product is supplied as a solid, is soluble in water at concentrations of at least 19.88 mg/mL and in DMSO at at least 399.3 mg/mL, and is insoluble in ethanol, as reported in the product specifications. Aqueous working solutions should be made fresh, protected from repeated handling, and used promptly rather than stored long term.
3. Establish receptor-proximal activity. Test a logarithmic concentration series in a receptor-expressing cell system before moving to a disease model. Confirm that basal cAMP is stable, normalize to cell number or total protein, and collect an early time point before interpreting later transcriptional effects.
4. Layer in phenotype assays. In valve endothelial cells, pair PTH treatment with VE-cadherin, ZO-1, and mesenchymal-marker measurements, along with migration or barrier assays. Transfer conditioned medium to valvular interstitial cells to test whether endothelial signaling promotes osteogenic behavior through a paracrine mechanism.
5. Use orthogonal endpoints. If calcification increases, verify it with at least one complementary method, such as a mineral assay, imaging, or osteogenic gene panel. A single endpoint can be distorted by altered cell density, toxicity, or matrix accumulation.

Protocol Parameters

• Primary stock: Reconstitute the solid in sterile water at 0.1 mg/mL, mix gently for 10 minutes at 20–25°C, and dispense into 50–100 µL single-use aliquots; prepare fresh working dilutions on the day of treatment.
• Receptor signaling screen: Test 0.01, 0.1, 1, 10, and 30 nM PTH (1-34) for 15–30 minutes at 37°C, with at least three technical wells per concentration; use the 0.22 nM cAMP activity value as a rationale for including subnanomolar concentrations in a refined series.
• EndMT pilot: Expose valve endothelial cells to 0.1, 1, 10, and 24 nM for 24 and 48 hours, then collect matched lysates and conditioned medium; treat the 24 nM condition as an upper exploratory point rather than a universal optimum.
• Bone-model comparison: For an appropriately approved animal study, compare subcutaneous doses of 10 and 40 µg/kg/day over 4 weeks, matching the dose-and-duration framework reported in the product’s referenced rat study; include vehicle controls and separate biochemical from histological endpoints.

Key Innovation from the Reference Study

The key advance in the 2026 Biochemical Pharmacology study was not simply showing that CKD is associated with valve calcification. The investigators generated endothelial-specific Foxp1 overexpression mice, termed Foxp1EC-OE, and used that model to position endothelial Foxp1 upstream of a Jagged-1/Notch signaling mechanism. Their findings connected Foxp1-mediated repression of the Jagged-1 promoter with reduced Notch activation, lower TGF-β1 secretion, less endothelial-to-mesenchymal transition, and weaker osteogenic conversion of valvular interstitial cells. The study also linked restored endothelial integrity with reduced HMGB1-driven macrophage infiltration. The full mechanistic framework is described in the reference study.

This result changes practical assay design. Instead of asking only whether PTH increases mineral deposition, researchers can ask which cellular compartment responds first and whether endothelial Foxp1 status changes the response. A strong workflow therefore includes a PTH-treated endothelial monolayer, Foxp1 gain- or loss-of-function conditions where available, Jagged-1/Notch pathway measurements, and conditioned-medium transfer into valvular interstitial cells. ChIP-qPCR at the Jagged-1 promoter can test transcriptional regulation, whereas TGF-β1 measurements and VIC osteogenic markers provide a functional bridge between the endothelial signal and calcification.

The reference study should not be read as evidence that SKU A1129 was used in that exact publication or that the product alone reproduces the mouse CKD phenotype. Its value for product selection is conceptual: the PTH stimulus can be integrated into a compartment-resolved assay that tests the proposed endothelial-to-interstitial-cell sequence rather than treating calcification as an isolated endpoint.

Advanced applications and comparative advantages

From receptor pharmacology to bone metabolism research

The fragment’s defined identity supports concentration-response comparisons across osteoblast-like cells, kidney-derived cells, endothelial cultures, and co-culture systems. In an osteoporosis model, investigators can compare intermittent and sustained exposure schedules, then relate receptor activity to bone formation or mineralization measurements. In kidney research, the same reagent can be used to examine how PTH-responsive cells interact with calcium and phosphate conditions that mimic altered renal physiology.

Compared with relying on endogenous PTH secretion, an exogenous PTH (1-34) peptide fragment provides control over timing, nominal dose, and washout. Compared with an undefined conditioned medium, it reduces uncertainty about the initiating ligand. These are experimental advantages, not proof of superiority in every model. Species compatibility, receptor abundance, serum composition, peptide adsorption, and exposure duration still need to be validated for each system.

Connecting bone, kidney, and valve assays

The article Parathyroid hormone (1-34) (human) in Bone and Kidney Models complements this workflow by emphasizing cross-tissue modeling; it can help researchers extend a receptor-validated PTH exposure into bone and renal systems. The resource Parathyroid hormone (1-34) (human): New Frontiers in Calcification and EndMT Research is a closer extension of the present use case because it focuses on the relationship between PTH, endothelial state, and calcification. Together, these resources support a staged strategy: validate signaling first, then add tissue-specific phenotypes and intercellular communication.

Why this cross-domain matters, maturity, and limitations

Bone remodeling and CKD-associated valvular calcification share calcium-related biology but are not interchangeable models. The reference study supports a mature mechanistic hypothesis for Foxp1, Jagged-1/Notch, EndMT, TGF-β1, and VIC osteogenic activation in CKD-related valve disease. It does not establish that a bone-cell response predicts a valve response, nor that a short cell-culture exposure captures chronic renal dysfunction. Cross-domain experiments are therefore most defensible when they preserve the same PTH dose logic, include tissue-specific controls, and report receptor signaling separately from disease-level conclusions.

Troubleshooting and optimization tips

Weak or variable cAMP response

First verify receptor expression, cell density, stimulation time, and plate uniformity. Prepare fresh dilutions from a single-use aliquot and include concentrations below and above the reported cAMP activity range. If basal cAMP is high, reduce handling time before stimulation and check whether serum or other agonists are activating the pathway. A poor response in one cell line does not invalidate the peptide; it may indicate limited PTH1R abundance or altered coupling.

Precipitation or apparent loss of activity

Do not use ethanol as a solvent, because the product is reported to be insoluble in ethanol. Inspect the working solution after dilution, avoid abrupt addition into a small volume of concentrated salts or protein-rich medium, and use gentle mixing. If the vehicle is DMSO, keep the final vehicle concentration identical across wells and as low as practical. A visible precipitate should be treated as a dosing failure, not as evidence of biological inactivity.

EndMT signal without consistent calcification

EndMT and mineral deposition occur on different experimental timescales. Confirm early loss of endothelial markers and increased motility before expecting a late calcification signal. Normalize mineral measurements to viable cell number or total protein, and test conditioned medium separately from direct PTH exposure. If VIC responses are inconsistent, standardize passage number, matrix coating, confluence, and the interval between endothelial treatment and medium transfer.

Unexpected toxicity or nonspecific remodeling

Run a viability and morphology check alongside every concentration series. If toxicity appears only at the highest condition, narrow the range around receptor-relevant concentrations rather than interpreting the phenotype as pathway-specific. For CKD-oriented experiments, independently model the renal or inflammatory context and the PTH stimulus; combining too many stressors in one step makes it difficult to assign causality to PTH/PTHrP receptor signaling.

Future outlook

Future studies can use this peptide to test whether endothelial Foxp1 status changes the response to a controlled PTH challenge, whether Jagged-1/Notch activity tracks with EndMT across model systems, and whether reduced TGF-β1 signaling is accompanied by less VIC osteogenic activation. The most informative direction is not simply more dose escalation, but better temporal and cellular resolution: receptor signaling first, endothelial integrity next, paracrine transfer afterward, and calcification last. That sequence follows the mechanistic logic of the reference study while keeping the product’s role—as a defined research stimulus—experimentally clear.